Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.73 |
| ▸ | EML4 | Q9HC35 | 6/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | CIT | O14578 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | BUB1 | O43683 | 1/20 | 0.46 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.46 |
| ▸ | STK16 | O75716 | 1/20 | 0.46 |
| ▸ | STK10 | O94804 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | LATS1 | O95835 | 1/20 | 0.46 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.46 |
| ▸ | YES1 | P07947 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16207286 | 0.94 | EGFR (0.65) | EGFREML4ALKBMPR1BPLK4 | |
| SCHEMBL16206698 | 0.91 | EGFR (0.61) | EGFREML4ALKRETROS1 | |
| SCHEMBL16206688 | 0.90 | EGFR (0.59) | EGFREML4ALKRETROS1 | |
| SCHEMBL16207282 | 0.90 | EGFR (0.79) | EGFREML4ALKBMPR1BPLK4 | |
| SCHEMBL16206691 | 0.89 | EGFR (0.58) | EGFREML4ALKRETROS1 | |
| SCHEMBL16195736 | 0.88 | EGFR (0.71) | EGFREML4ALKRETROS1 | |
| SCHEMBL16207276 | 0.88 | EML4 (0.63) | EGFREML4ALKBMPR1BPLK4 | |
| SCHEMBL16206701 | 0.88 | EGFR (0.64) | EGFREML4ALKAURKARET | |
| SCHEMBL16207277 | 0.87 | ALK (0.58) | EGFREML4ALKRETROS1 | |
| SCHEMBL16196158 | 0.86 | EGFR (0.61) | EGFREML4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805940-B1 | PYRAZINE CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| EP-2805940-A1 | PYRAZINE CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | EGFR, ERBB2, ALK | EGFR 1/4885EML4 158/4885ALK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.